Olema Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Olema Pharmaceuticals's earnings have been declining at an average annual rate of -39.3%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-39.3%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -38.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
Revenue & Expenses BreakdownBeta
How Olema Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -97 | 19 | 86 |
| 30 Sep 23 | 0 | -96 | 20 | 82 |
| 30 Jun 23 | 0 | -97 | 22 | 80 |
| 31 Mar 23 | 0 | -110 | 24 | 89 |
| 31 Dec 22 | 0 | -105 | 25 | 82 |
| 30 Sep 22 | 0 | -100 | 25 | 77 |
| 30 Jun 22 | 0 | -95 | 25 | 72 |
| 31 Mar 22 | 0 | -79 | 23 | 56 |
| 31 Dec 21 | 0 | -71 | 20 | 51 |
| 30 Sep 21 | 0 | -60 | 18 | 41 |
| 30 Jun 21 | 0 | -52 | 16 | 34 |
| 31 Mar 21 | 0 | -38 | 12 | 24 |
| 31 Dec 20 | 0 | -24 | 8 | 14 |
| 30 Sep 20 | 0 | -15 | 4 | 8 |
| 31 Dec 19 | 0 | -4 | 0 | 4 |
Quality Earnings: OLMA is currently unprofitable.
Growing Profit Margin: OLMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OLMA is unprofitable, and losses have increased over the past 5 years at a rate of 39.3% per year.
Accelerating Growth: Unable to compare OLMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OLMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: OLMA has a negative Return on Equity (-38.07%), as it is currently unprofitable.